These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 24822054)
1. Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains. Nico D; Gomes DC; Alves-Silva MV; Freitas EO; Morrot A; Bahia D; Palatnik M; Rodrigues MM; Palatnik-de-Sousa CB Front Immunol; 2014; 5():189. PubMed ID: 24822054 [TBL] [Abstract][Full Text] [Related]
2. A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Alves-Silva MV; Nico D; Morrot A; Palatnik M; Palatnik-de-Sousa CB Front Immunol; 2017; 8():100. PubMed ID: 28280494 [TBL] [Abstract][Full Text] [Related]
3. The F1F3 Recombinant Chimera of Alves-Silva MV; Nico D; de Luca PM; Palatnik de-Sousa CB Front Immunol; 2019; 10():724. PubMed ID: 31024556 [No Abstract] [Full Text] [Related]
4. Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection. Nico D; Gomes DC; Palatnik-de-Sousa I; Morrot A; Palatnik M; Palatnik-de-Sousa CB Front Immunol; 2014; 5():273. PubMed ID: 24966857 [TBL] [Abstract][Full Text] [Related]
5. Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response. Nico D; Claser C; Borja-Cabrera GP; Travassos LR; Palatnik M; Soares IS; Rodrigues MM; Palatnik-de-Sousa CB PLoS Negl Trop Dis; 2010 Nov; 4(11):e866. PubMed ID: 21085470 [TBL] [Abstract][Full Text] [Related]
6. Barbosa Santos ML; Nico D; de Oliveira FA; Barreto AS; Palatnik-de-Sousa I; Carrillo E; Moreno J; de Luca PM; Morrot A; Rosa DS; Palatnik M; Bani-Corrêa C; de Almeida RP; Palatnik-de-Sousa CB Front Immunol; 2017; 8():227. PubMed ID: 28321221 [TBL] [Abstract][Full Text] [Related]
7. Nucleoside Hydrolase NH 36: A Vital Enzyme for the Palatnik-de-Sousa CB Front Immunol; 2019; 10():813. PubMed ID: 31040850 [TBL] [Abstract][Full Text] [Related]
8. F1 Domain of the Carrillo E; Fernandez L; Ibarra-Meneses AV; Santos MLB; Nico D; de Luca PM; Correa CB; de Almeida RP; Moreno J; Palatnik-de-Sousa CB Front Immunol; 2017; 8():750. PubMed ID: 28747911 [TBL] [Abstract][Full Text] [Related]
9. NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis. Nico D; Martins Almeida F; Maria Motta J; Soares Dos Santos Cardoso F; Freire-de-Lima CG; Freire-de-Lima L; de Luca PM; Maria Blanco Martinez A; Morrot A; Palatnik-de-Sousa CB Front Immunol; 2018; 9():967. PubMed ID: 29867949 [TBL] [Abstract][Full Text] [Related]
10. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920 [TBL] [Abstract][Full Text] [Related]